Study of Gene Variations Linked to Cancer Cachexia in Adults with Advanced Pancreatic Adenocarcinoma

What this Trial Is About

Researchers are studying pancreatic adenocarcinoma PDAC, a serious type of cancer often complicated by cancer cachexia CC, a syndrome marked by loss of muscle mass and impaired function that is not reversed by usual nutritional support. CC is common in over 75% of advanced PDAC cases and worsens patient outcomes. This study aims to investigate genetic variations polymorphisms that may be linked to CC in PDAC patients to better understand its causes and potential future treatments. The study involves collecting specimens such as blood or buccal swabs from 100 patients with locally advanced unresectable or metastatic PDAC. These specimens will be analyzed for gene single nucleotide polymorphisms alongside clinical data like patient weights, imaging for muscle loss sarcopenia, and selected laboratory tests. Specimen collection occurs during standard care visits after confirming eligibility, and all data and specimens will be deidentified before analysis and sharing. Participants will undergo assessments focused on genetic and clinical factors related to CC. Researchers will review imaging and clinical data up to three years to study sarcopenia, overall survival, and progression-free survival. The main outcome is cancer cachexia measured around three months. Personal health information is collected but handled confidentially. Participation duration can extend up to three years with no interventional treatments involved, as this is an observational study.

Assoc. of Genomic Polymorphisms With Cancer Cachexia in Subjects With Panc Adenocarcinoma